INTRACRINE DYNAMICS OF CYP17A1 ACTIVITIES IN HUMAN CASTRATION RESISTANT PROSTATE CANCER

被引：0
|
作者：
Kosaka, Takeo
Miyajima, Akira
Maeda, Takahiro
Nagata, Hirohiko
Yasumizu, Yota
Kikuchi, Eiji
Oya, Mototsugu
机构：
来源：
JOURNAL OF UROLOGY | 2013年 / 189卷 / 04期
关键词：
D O I：
10.1016/j.juro.2013.02.1900
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
506
引用
收藏
页码：E207 / E208
页数：2
相关论文
共 50 条
  • [1] CYP17A1 inhibitors in castration-resistant prostate cancer
    Gomez, Lissette
    Kovac, Jason R.
    Lamb, Dolores J.
    STEROIDS, 2015, 95 : 80 - 87
  • [2] Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer
    Kosaka, Takeo
    Miyajima, Akira
    Yasumizu, Yota
    Miyazaki, Yasumasa
    Kikuchi, Eiji
    Oya, Mototsugu
    STEROIDS, 2014, 92 : 39 - 44
  • [3] Relevance of CYP17A1 Blockade in Clones of Castration-resistant Prostate Cancer
    Kumagai, J.
    Erkens-Schulze, S.
    Dits, N. F. J.
    de Wit, R.
    van Weerden, W. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 90 - 91
  • [4] A Novel Communication Role for CYP17A1 in the Progression of Castration-Resistant Prostate Cancer
    Locke, Jennifer A.
    Fazli, Ladan
    Adomat, Hans
    Smyl, Jil
    Weins, Kristin
    Lubik, Amy A.
    Hales, Dale B.
    Nelson, Colleen C.
    Gleave, Martin E.
    Guns, Emma S. Tomlinson
    PROSTATE, 2009, 69 (09): : 928 - 937
  • [5] CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone
    Salvi, Samanta
    Casadio, Valentina
    Burgio, Salvatore Luca
    Conteduca, Vincenza
    Rossi, Lorena
    Menna, Cecilia
    Carretta, Elisa
    Costantini, Matteo
    Zoli, Wainer
    De Giorgi, Ugo
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2016, 31 (03): : E264 - E269
  • [6] CYP17A1 expression in prostate cancer
    Giatromanolaki, A.
    Fasoulaki, V.
    Kalamida, D.
    Sivridis, E.
    Koukourakis, M.
    VIRCHOWS ARCHIV, 2018, 473 : S255 - S256
  • [7] Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer
    Ripert, T.
    Crouzet, S.
    Ploussard, G.
    De La Taille, A.
    Robert, G.
    PROGRES EN UROLOGIE, 2013, 23 : S16 - S22
  • [8] Structure-based discovery of selective CYP17A1 inhibitors for Castration-resistant prostate cancer treatment
    Omoboyowa, Damilola A.
    Balogun, Toheeb A.
    Saibu, Oluwatosin A.
    Chukwudozie, Onyeka S.
    Alausa, Abdullahi
    Olubode, Samuel O.
    Aborode, Abdullahi T.
    Batiha, Gaber E.
    Bodun, Damilola S.
    Musa, Sekinat O.
    BIOLOGY METHODS & PROTOCOLS, 2022, 7 (01):
  • [9] HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer
    Almassi, Nima
    Reichard, Chad
    Li, Jianbo
    Russell, Carly
    Perry, Jaselle
    Ryan, Charles J.
    Friedlander, Terence
    Sharifi, Nima
    JAMA ONCOLOGY, 2018, 4 (04) : 554 - 557
  • [10] Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)
    Bremmer, Felix
    Jarry, Hubertus
    Strauss, Arne
    Behnes, Carl Ludwig
    Trojan, Lutz
    Thelen, Paul
    SPRINGERPLUS, 2014, 3
12345